AccScience Publishing / ARNM / Volume 1 / Issue 1 / DOI: 10.36922/arnm.0883
Cite this article
Journal Browser
Volume | Year
News and Announcements
View All

A case report of refractory pulmonary adenocarcinoma

Haiyan Li1 Chifeng Xu1 Xia Lu1*
Show Less
1 Department of Nuclear Medicine, Northern Jiangsu People’s Hospital, Yangzhou, China
Submitted: 29 April 2023 | Accepted: 16 June 2023 | Published: 28 June 2023
© 2023 by the Author(S). Licensee AccScience Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( )

As one of the most common types of carcinomas, lung cancer has high incidence and mortality rates. Among the pathological types of lung cancer, pulmonary adenocarcinoma is the most prevalent. Advancements in medical treatments have contributed to improved prognosis in pulmonary adenocarcinomas. However, this case report revealed a rare refractory lung adenocarcinoma, suggesting that further research and robust management strategies are needed to improve clinical outcomes. In this regard, 18F-fluorodeoxyglucose positron emission tomography/ computed tomography plays a very important role in the comprehensive evaluation of glucose metabolic activity in lung adenocarcinoma and the progression of metastasis in distant organs.

Pulmonary adenocarcinoma
18F-fluorodeoxyglucose positron emission tomography/computed tomography
Lvyang Jinfeng talents attracting plan
  1. Moreira AL, Ocampo PSS, Xia Y, et al., 2020, A grading system for invasive pulmonary adenocarcinoma: A proposal from the international association for the study of lung cancer pathology committee. J Thorac Oncol, 15: 1599–1610.


  1. Travis WD, Brambilla E, Van Schil P, et al., 2011, Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification. Eur Respir J, 38: 239–243.


  1. Vilhonen H, Kurki S, Laitinen T, et al., 2019, Retrospective evaluation of lung adenocarcinoma patients progressing on 1st line chemotherapy. Medicina (Kaunas), 55: 743.


  1. Xu L, Qi Q, Zhang Y, et al., 2019, Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study. Lung Cancer, 133: 23–31.


  1. Paliwal P, Rajappa S, Santa A, et al., 2017, Clinical profile and outcomes of patients with Stage IV adenocarcinoma of lung: A tertiary cancer center experience. Indian J Cancer, 54: 197–202.


  1. Feng Y, Tang L, Wang H, et al., 2023, Immune checkpoint inhibitors combined with angiogenic inhibitors in the treatment of locally advanced or metastatic lung adenocarcinoma patients. Cancer Immunol Immunother, 72: 449–459.


  1. Xu Z, Hao X, Lin L, et al., 2021, Concurrent chemotherapy and first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first-line treatment in advanced lung adenocarcinoma harboring an EGFR mutation. Thorac Cancer, 12: 2233–2240.


  1. Paik SS, Hwang IK, Park MJ, et al., 2018, Pemetrexed continuation maintenance versus conventional platinum-based doublet chemotherapy in EGFR-negative lung adenocarcinoma: Retrospective analysis. Tuberc Respir Dis (Seoul), 81: 148–155.


  1. Xu X, Li R, Zhu, P, et al., 2021, Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: A retrospective real-world study. World J Surg Oncol, 19: 231.


  1. Oncology Society of Chinese Medical Association, Chinese Medical Association Publishing House, 2022, Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2022 edition). Zhonghua Zhong Liu Za Zhi, 44: 457–490.
Conflict of interest
There is no conflicts of interest in this study.
Back to top
Advances in Radiotherapy & Nuclear Medicine, Electronic ISSN: 2972-4392 Print ISSN: TBA, Published by AccScience Publishing